CTC Bio

CTC Bio EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of CTC Bio (060590.KQ) as of Oct 29, 2026 is 31.66. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 47.60 — a change of -33.48% (lower).

EV/FCF

31.66

YoY

-33.48%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of CTC Bio is 2025 31.66 . EV/FCF (Enterprise Value to Free Cash Flow) of CTC Bio was 2024 47.60 . It decreases by -33.48% lower compared to the previous year.

The CTC Bio EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-40.63 KRW
Jan 1, 2019
-245.38 KRW
Jan 1, 2020
-102.97 KRW
Jan 1, 2021
26.91 KRW
Jan 1, 2022
7.55 KRW
Jan 1, 2023
17.12 KRW
Jan 1, 2024
47.60 KRW
Jan 1, 2025
31.66 KRW
The CTC Bio EV/FCF history
YEAREV/FCFYoY
31.66-33.48%
47.60+178.01%
17.12+126.74%
7.55-71.94%
26.91-126.14%
-102.97-58.04%
-245.38+503.94%
-40.63-17.59%
-49.30+97.61%
-24.95+239.56%
-7.35+82.16%
-4.03—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CTC Bio Stock analysis

What does CTC Bio do? CTC Bio, Inc. generates revenue through the manufacture and sale of pharmaceuticals, including anticancer agents, antibiotics, bone injury treatments, antiulcer agents, and blood flow stimulants. The company also produces veterinary drugs such as vaccines, antibiotics, immune enhancers, enzymes, organic acid, and avian influenza-related agents, alongside animal feed supplements like pigments, kapok seed meal, and sesame meal. Functional food products, including enzymes and lactobacillus for dairy applications, form another revenue stream. The firm distributes these products domestically and internationally, targeting healthcare providers, veterinarians, and food manufacturers. The company's pharmaceutical segment serves medical professionals seeking treatments for cancer, infections, and gastrointestinal issues. Veterinary drug sales cater to animal health practitioners requiring vaccines and antibiotics for livestock. Animal feed supplements are sold to agricultural businesses, while functional food ingredients target dairy producers. CTC Bio, Inc. leverages its in-house pharmaceutical manufacturing technology and know-how to support product development and maintain competitive pricing. Revenue streams include direct sales of pharmaceuticals, veterinary drugs, animal feed supplements, and functional food ingredients. Domestic markets absorb the majority of these products, with international distribution expanding its reach. The company's focus on integrated production of pharmaceuticals, animal health solutions, and functional food components ensures consistent demand across multiple industry segments. CTC Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CTC Bio stock

EV/FCF (Enterprise Value to Free Cash Flow) of CTC Bio is 31.66 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of CTC Bio changed from 47.60 to 31.66, representing a -33.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) CTC Bio since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s CTC Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — CTC Bio

All Key Metrics — CTC Bio